Category: HypertensionSyndicate content

Can Big Data help detect silent hypertension? | MassDevice.com On Call

July 17, 2014 by Arezu Sarvestani

Researchers develop a "surveillance system" to monitor patients' electronic health records for signs of undiagnosed hypertension.

MassDevice.com On Call

MASSDEVICE ON CALL — A computer algorithm may be able to help physicians monitor patients for signs of hypertension, a disease known as "the silent killer."

Researchers at Northwestern Medicine developed a trio of algorithms to review patients' electronic health records and alert healthcare providers that a patient may have or may be developing hypertension.

Simple, not sexy: Twitter docs weigh in on the future of renal denervation

May 28, 2014 by Arezu Sarvestani

Twitter-savvy physicians and researchers mull over the latest clinical results for Medtronic's renal denervation technology, calling for more common sense and less hype in treating hypertension.

Simple, not sexy: Twitter's docs weigh in on the future of renal denervation

EuroPCR 2014: Looking for hope for renal denervation

May 27, 2014 by Arezu Sarvestani

Doctors and researchers at this year's EuroPCR conference look for answers in Medtronic's landmark SYMPLICITY HTN-3 clinical trial, which failed to find that renal denervation works against hypertension.

EuroPCR 2014: Renal denervation remains in the limelight

Amid the hand-wringing and back-pedaling surrounding renal denervation, some physicians are still looking for ways to use the technology to treat patients with hypertension.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

EuroPCR 2014: St. Jude touts EnligHTN data amid renal denervation backlash

May 22, 2014 by Arezu Sarvestani

St. Jude Medical says that its next-gen EnligHTN renal denervation system appears safe and effective in treating hypertension, but docs at this year's EuroPCR conference are calling for more robust clinical trials.

EuroPCR 2014: St. Jude touts EnligHTN data amid renal denervation backlash

EuroPCR 2014: Docs say renal denervation ads are putting 'marketing before science'

May 21, 2014 by Arezu Sarvestani

The marketing push for hypertension-treating renal denervation technology, clinical darling turned black sheep, has some doctors raising eyebrows at the EuroPCR conference in Paris this week.

EuroPCR 2014: Renal denervation looks alive in Europe

Attendees at this year's EuroPCR conference in Paris cast a wary eye on medical device makers' efforts to promote renal denervation in treatment of hypertension, taking to Twitter to note and sometimes chide companies for putting "marketing before science."

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Device makers take big writedowns on renal denervation

May 13, 2014 by Brad Perriello

Boston Scientific, Medtronic and Covidien take millions in write-downs on their renal denervation assets after the failure of Medtronic's Symplicity-3 trial.

Device makers take big writedowns on renal denervation

Bakris: Symplicity-3 a prologue for renal denervation | MassDevice.com On Call

April 22, 2014 by MassDevice

Dr. George Bakris, co-principal investigator in Medtronic's Symplicity-3 trial, says renal denervation needs more study before attempting more clinical trials.

MassDevice.com On Call

MASSDEVICE ON CALL — Dr. George Bakris, the co-principal investigator for Medtronic's (NYSE:MDT) failed Symplicty-3 renal denervation trial, believes further clinical work should be tabled until a few key questions about the therapy are answered.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp